Brexanolone

(Zulresso®)

Zulresso®

Latest News

loading GIF

Drug updated on 4/18/2024

Dosage FormInjection (intravenous; 100 mg/20 mL [5 mg/mL])
Drug ClassNeuroactive steroid gamma-aminobutyric acid modulators
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of postpartum depression (PPD) in patients 15 years and older.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Brexanolone (Zulresso) is indicated for the treatment of postpartum depression (PPD) in individuals 15 years and older. It has demonstrated significantly higher percentages of patients achieving response and remission rates in the Hamilton Depression Rating Scale (HAM-D) for PPD when compared to placebo, indicating robust efficacy.
  • The information was synthesized from four systematic reviews/meta-analyses documents on Zulresso's use for treating PPD. However, only three studies were reviewed due to an error encountered during one document retrieval.
  • A single infusion of brexanolone showed a rapid antidepressant effect starting after 24 hours, peaking at 36 and 60 hours, and lasting up to seven days, showcasing its potential for providing quick relief from PPD symptoms.
  • In comparison with other treatments for PDD such as estradiol or paroxetine based on cumulative probability rankings from a network meta-analysis involving eleven studies with nine hundred forty-four participants; brexanolone may not be the most effective option available despite being among the top treatments.
  • Concerning safety and tolerability; while some individuals discontinued treatment due to reasons suggesting concerns about its tolerability, adverse reactions at severe levels were not significantly greater than those experienced by placebo users. Moreover, early dropouts suggest that acceptance might be limited potentially due to the mode of administration or side effects impacting their decision to continue treatment.
  • Studies primarily focused on women suffering from postpartum depression without detailed subgroup analyses based on demographic factors. Hence, data are mostly applicable to this population without specific indications of differential effects on subpopulations available for the time period under review.